Het Nieuwsblad published on Tuesday, according to news agency. "Not even enough to warrant a conditional marketing licence", he said.
European regulators have only received some information about the vaccine, Wathion said. "We need additional data about the quality of the vaccine.
And after that, the company has to formally apply," Wathion said. AstraZeneca told Reuters last week that its COVID-19 vaccine should be effective against the new coronavirus variant, adding that studies were under way to fully probe the impact of the mutation.
It has submitted a full data package about its vaccine to the British medicines regulator, British health minister said. Serum Institute of India, the local maker of the Oxford-AstraZeneca coronavirus.